亚洲免费av电影一区二区三区,日韩爱爱视频,51精品视频一区二区三区,91视频爱爱,日韩欧美在线播放视频,中文字幕少妇AV,亚洲电影中文字幕,久久久久亚洲av成人网址,久久综合视频网站,国产在线不卡免费播放

        ?

        Sudden cardiac death in a case of Crohn's disease with COVID-19: A case report

        2022-07-02 05:53:02NeerajKumarSubhajitGhoshAbhyudayKumarSanjeevKumarPremKumar
        Journal of Acute Disease 2022年3期
        關(guān)鍵詞:腔室流線擋板

        Neeraj Kumar, Subhajit Ghosh, Abhyuday Kumar, Sanjeev Kumar, Prem Kumar

        Departments of 1Trauma & Emergency, 2Anaesthesiology, 3CTVS, and 4Radiology, All India Institute of Medical Sciences, Patna, India

        ABSTRACT

        KEYWORDS: COVID-19; Sudden cardiac death; Chron’s disease

        1. Introduction

        Inflammatory bowel diseases (IBD) like Crohn’s disease (CD)and ulcerative colitis (UC) are chronic inflammatory diseases of the intestines that may present with many venous vascular comorbidities such as deep venous thrombosis or portal vein thrombosis. These chronic systemic inflammations may lead to endothelial dysfunction and platelet aggregation and serve as a precursor to the development of atherosclerosis and coronary artery disease (CAD)[1]. As per the literature, SARS-CoV-2 can lead to unfavorable outcomes in elderly patients with comorbidities, for example, cardiovascular dysfunction[2]. Sudden cardiac death (SCD) has emerged as one of the most challenging concerns amid the COVID-19 pandemic[3].Although the direct causal association between SCD and COVID-19 remains unproven, but some published data may suggest a plausible association.

        2. Case report

        Departmental Ethics Committee, All India Institute of Medical Sciences Patna, Bihar, India, approved the reporting of this case, and the informed consent was obtained from the patient’s relatives.

        A 75-year COVID-19 patient was admitted to our intensive care unit because of the shortness of breath for the last 2 days. He was a known case of Crohn’s disease and hypothyroidism and was on tablet mesalamine 1 g and tablet levothyroxine 25 μg daily. He had stable vitals and maintained saturation on the non-rebreathing mask with a reservoir bag. As per our institutional COVID-19 management protocol, remdesivir, antibiotics, steroids, low molecular weight heparin, tablet zinc, tablet vitamin C, and other supportive treatment were started. Because of increased inflammatory markers, itolizumab was given to the patient on the 2nd day. Artery blood gas was within acceptable limits with a PaO2/FiO2ratio of 121. The normal arterial blood gases were PH of 7.36, PaO2of 78 mmHg, PaCO2of 33 mmHg, HCO3of 21 mmol/L. The chest X-Ray finding was typically suggestive of COVID-19 with patchy areas of ground-glass opacity in the middle and lower zones in the right and middle zone in the left,with normal costophrenic angle (Figure 1). On the 3rd day, oxygen requirement was further increased, and oxygen saturation dropped below 90% with a respiratory rate of 38-40 rates per minute. He was put on a high-flow nasal oxygenation machine with a FiO2of 0.8 and with a flow rate of 5 L/ min. On the 4th day, the patient’s condition was improved, and oxygen saturation was maintained between 95%-97% on transnasal high flow oxygen therapy with FiO2of 0.6 and at a flow rate of 5 L/min. Routine investigations on days three and four were almost normal except for the inflammatory markers which were raised (Table 1). A day-by-day clinical progression is shown in Table 2.

        Figure 1. The chest X-ray (AP-view) of a 75-year-old man with COVID-19.White arrows show extensive opacities in bilateral lungs.

        Table 1. Day wise laboratory and inflammatory markers values.

        Table 2. Clinical course of the patient during ICU stay.

        On the 5th day, the patient complained of sudden chest pain with respiratory distress. A 12-lead electrocardiograph was taken which showed no significant ST-segment change, and trop T was negative. 2-D bedside echocardiography did not show any evidence of pulmonary embolism with normal chamber size and normal left ventricular ejection fraction. But the patient immediately went into bradycardia and followed by asystole. Cardiopulmonary resuscitation was initiated promptly per Advanced Cardiac Life Support protocol; all reversible causes, including tension pneumothorax, cardiac tamponade, and electrolyte/metabolic disturbances were ruled out. However, the patient was not revived and was declared dead.

        3. Discussion

        The mechanism of SCD in COVID-19 can be multifactorial. However,it remains difficult to ascertain the most common mechanism involved due to a lack of data. Both tachyarrhythmia and bradyarrhythmia have been reported in COVID-19. Fatal arrhythmias in COVID-19 may also result from hypoxia, cardiac dysfunction, severe systemic inflammatory state, electrolyte derangements, intravascular volume imbalances,and drug side effects[4]. Guo et al.[5] suggested life-threatening arrhythmias have been variably reported from 10% to 16% of patients hospitalized for severe COVID-19, more commonly in the setting of elevated troponin indicating myocardial injury. Some of the proposed causes of sudden cardiac death in COVID-19 are acute myocarditis(stress-induced cardiomyopathy), acute coronary syndrome, hypoxia,pulmonary thromboembolism, coronary thrombosis, stroke, cardiac tamponade, electrolyte imbalance, underlying channelopathies, and drug-induced arrhythmias. Direct arrhythmogenesis by COVID-19 cytokines has a direct electrophysiological effect on the myocardium,IL-6, tumor necrosis factor-α, and IL-1 can prolong ventricular action potential duration. These cytokines may induce cardiac sympathetic system hyperactivation, which can trigger life-threatening arrhythmic events in patients with long QT[6]. In our case, QT/QTc was 348/452 ms, so the possibility of any QTc prolongation was ruled out. The deep vein thrombosis and pulmonary embolism was also ruled out because of normal echocardiography findings with normal d-dimer and prothrombin time.

        Studies have found that IBDs are associated with an increased risk of CAD, cerebrovascular diseases, and peripheral arterial diseases[7]. High levels of circulating cytokines and C-reactive protein are characteristic of IBD, and it is therefore expected to contribute to endothelial dysfunction and atherogenesis. The possible causes of increased cardiovascular events in patients with IBD can be raised inflammatory markers, endothelial dysfunction, hypercoagulability, and release of endotoxins and lipoproteins[7].

        The drug mesalazine (5-ASA) is efficacious in active Crohn’s and ulcerative colitis and are generally regarded as a safe and well-tolerated medication[8]. Cardiac hypersensitivity to 5-ASA therapy leading to myocarditis has been reported in some case studies, and the first reported death from myocarditis associated with mesalazine use was in 1990[9]. In documented literature, hypersensitivity appears to be an idiosyncratic reaction rather than dose-dependent due to its occurrence in patients on very low amounts of mesalazine such as 0.5 g a day[10].

        In our case, sudden cardiac death was possibly due to cardiovascular complications caused by cytokine storm syndrome (raised inflammatory markers) and idiosyncratic reaction with mesalazine use. Our patient had a high-risk factor for cardiovascular complications due to COVID-19, IBD, and mesalazine. Mesalazine is very safe and efficacious in the management of inflammatory bowel disease but we should be aware of its serious and potentially life-threatening complications that may occur especially if it has to be used in COVID-19 infected patients.

        To sum up, immunosuppressants in hospitalized COVID-19 patients should be continued with caution. There should be a baseline electrocardiograph to check QTc interval and look for other risk markers of tachy or bradyarrhythmias. Metabolic parameters including electrolytes, fluid volume, and acidosis should be actively sought and treated at the earliest possible, especially in the ICU. Every patient deserves risk stratification based on his/her clinical background with complete available information.

        Conflict of interest statement

        圖3無擋板結(jié)構(gòu),中心區(qū)域因氣流進(jìn)入時無阻擋,而以較大流速直接沖入腔室,從而產(chǎn)生流場擾動,且中心區(qū)域孔密度較高,邊緣孔密度小,邊緣流線較稀疏;

        The authors report no conflict of interest.

        Funding

        This study received no extramural founding.

        Authors’ contributions

        N.K.: Manuscript writing, proofreading, and final drafting; S.G.:Case management; manuscript writing A.K.: Final drafting; S.K.:Proofreading; P.K.: Proofreading.

        猜你喜歡
        腔室流線擋板
        平拋運(yùn)動中的“擋板”問題探究
        急冷增濕塔以及含硫廢棄物處理系統(tǒng)
        能源化工(2022年1期)2023-01-14 05:59:21
        燃燒器二次風(fēng)擋板開度對爐內(nèi)燃燒特性的影響
        類橢圓型采油螺桿泵舉升性能分析*
        幾何映射
        壓電傳感器
        傳感器世界(2019年3期)2019-02-17 13:07:26
        任意夾角交叉封閉邊界內(nèi)平面流線計算及應(yīng)用
        大型綜合交通樞紐流線組織設(shè)計
        CO2混相驅(qū)五點(diǎn)井網(wǎng)流線模擬
        玩意兒
        日本美女在线一区二区| 毛片在线播放亚洲免费中文网| 人妻精品久久中文字幕| 中文成人无字幕乱码精品区| aaa日本高清在线播放免费观看| 日韩国产自拍成人在线| 亚洲综合色区无码专区| 亚洲熟女综合一区二区三区| 十四以下岁毛片带血a级| 亚洲女同免费在线观看| 亚洲精品中文字幕二区| 国产精品天堂| 天天天天躁天天爱天天碰| 国产av无码专区亚洲版综合| 亚洲av手机在线播放| 视频一区中文字幕亚洲| 午夜短无码| 久久99国产乱子伦精品免费| 日日摸天天摸人人看| 久久中文骚妇内射| 久久久精品毛片免费观看| 色se在线中文字幕视频| 亚洲午夜无码视频在线播放| 国产jizzjizz视频免费看| 三年片免费观看大全国语| 妺妺窝人体色www看美女| 亚洲乱码中文字幕在线播放| 日本伦理视频一区二区| 免费 无码 国产精品| 国产精美视频| 少妇厨房愉情理伦片免费| 性色av浪潮av色欲av| 久久人妻无码一区二区| 亚洲av综合色区无码一区| 精品乱色一区二区中文字幕| 国产精品黄色av网站| 久久精品午夜免费看| 天天躁日日操狠狠操欧美老妇| 乱子真实露脸刺激对白| 亚洲国产av导航第一福利网| 国产男女无遮挡猛进猛出|